BioNerviano

Nerviano Medical Sciences (NMS) is a leading Italian clinical-stage biotechnology company focused on the discovery and development of innovative small molecule and antibody-drug conjugate (ADC) therapies for oncology. As the primary research engine of the NMS Group, the company leverages a proprietary kinase platform and advanced linker-payload technologies to target unmet needs in cancer treatment. NMS has a proven track record of success, having discovered several approved drugs including the ROS1/NTRK inhibitor entrectinib. The company operates an integrated model, providing research, development, and manufacturing services through its specialized subsidiaries to global pharmaceutical partners.